AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma...
AstraZeneca’s rare diseases unit Alexion has taken full control of Caelum Biosciences, gaining access to another rare disease drug, CAEL-101, which is a potential...
AstraZeneca has provided the US Food and Drug Administration (FDA) with encouraging study evidence that its antiviral cocktail candidate AZD7442 can prevent Covid-19...
AstraZeneca is building what it said is a “next-generation” active pharmaceutical ingredient (API) manufacturing plant for small molecules near Dublin, Ireland. A start...
With changes made to the age group of people receiving the AstraZeneca Covid-19 vaccine, the rare but troubling incidence of blood clots seen earlier this year has...
US biotech Regeneron is collaborating with AstraZeneca to research, develop and commercialize small molecule medicines targeting GPR75 for treating obesity.
The bark of the UK’s Competition and Markets Authority (CMA) evidently is worse than its bite – which in the case of AstraZeneca’s $39 billion acquisition of Alexion was...
EU competition authorities have approved AstraZeneca’s $39 billion takeover of US biopharma Alexion. Europe’s green light for the deal sealed in December 2020 follows the...
